Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD

E-ISSN： 1875-6557|6|2|112-118

ISSN： 1573-403X

Source： Current Cardiology Reviews, Vol.6, Iss.2, 2010-05, pp. : 112-118

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes

By Grieve Stuart M Ansquer Jean-Claude Keech Anthony C

Future Cardiology, Vol. 2, Iss. 6, 2006-11 ,pp. : 635-646

Future Medicine

Access to resources Recommend Favorite

New Player on An Old Field; the Keap1/Nrf2 Pathway as a Target for Treatment of Type 2 Diabetes and Metabolic Syndrome

Current Diabetes Reviews, Vol. 9, Iss. 2, 2013-03 ,pp. : 137-145

Bentham Science Publishers

Access to resources Recommend Favorite

Comparative Effectiveness of Pioglitazone and Rosiglitazone in Type 2 Diabetes, Prediabetes,and the Metabolic Syndrome: A Meta-Analysis

Current Diabetes Reviews, Vol. 3, Iss. 2, 2007-05 ,pp. : 127-140

Bentham Science Publishers

Access to resources Recommend Favorite

Visceral Adiposity Measurements, Metabolic and Inflammatory Profi le in Obese Patients with and Without Type 2 Diabetes Mellitus: A Crosssectional Analysis

Current Diabetes Reviews, Vol. 13, Iss. 1, 2016-12 ,pp. : 11-18

Bentham Science Publishers

Access to resources Recommend Favorite

Carbohydrate restriction as the default treatment for type 2 diabetes and metabolic syndrome

By Feinman Richard Volek Jeff

Scandinavian Cardiovascular Journal, Vol. 42, Iss. 4, 2008-01 ,pp. : 256-263

Informa Healthcare

Access to resources Recommend Favorite